Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Panitumumab + Chemoradiation for Esophageal Adenocarcinoma
NCT00757172Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2009
- Primary completion
- Nov 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Jan 2009; status: completed.
02
Drugs
panitumumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00757172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757172.